Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 2021 - Université de Montpellier
Article Dans Une Revue (Article De Synthèse) Expert Opinion on Therapeutic Patents Année : 2021

Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 2021

Résumé

Introduction : The hypoxic tumor microenvironment represents a persistent obstacle in the treatment of most solid tumors. In the past years, significant efforts have been made to improve the efficacy of anti-cancer drugs. Therefore, hypoxia-activated prodrugs (HAPs) of chemotherapeutic compounds have attracted widespread interest as a therapeutic means to treat hypoxic tumors. Areas covered : This updated review paper covers key patents published between 2006 and 2021 on the developments of HAP derivatives of anti-cancer compounds. Expert opinion : Despite significant achievements in the development of HAP derivatives of anti-cancer compounds and although many clinical trials have been performed or are ongoing both as monotherapies and as part of combination therapies, there has currently no HAP anti-cancer agent been commercialized into the market. Unsuccessful clinical translation is partly due to the lack of patient stratification based on reliable biomarkers that are predictive of a positive response to hypoxia-targeted therapy.

Domaines

Chimie
Fichier non déposé

Dates et versions

hal-03526759 , version 1 (14-01-2022)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Emilie Anduran, Ludwig Dubois, Philippe Lambin, Jean-Yves Winum. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 2021. Expert Opinion on Therapeutic Patents, 2021, 32 (1), pp.1-12. ⟨10.1080/13543776.2021.1954617⟩. ⟨hal-03526759⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

More